Related Experiment Video
Updated: Sep 7, 2025
11:43
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
Published on: November 30, 2016
12.8K
[Liver metastases-Non-colorectal, non-endocrine]
Stefan Heinrich1, Juliane Theurer1, Hauke Lang2
1Allgemein‑, Viszeral- u. Transplantationschirurgie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.
Chirurgie (Heidelberg, Germany)
|June 22, 2022
Summary
Liver resection can benefit selected patients with non-colorectal non-endocrine (NCNE) liver metastases. Advances in systemic treatments mean that modern liver surgery is becoming integral to multimodality care for these cancers.
Area of Science:
- Hepatobiliary surgery
- Surgical oncology
- Medical oncology
Background:
- Liver surgery for non-colorectal non-endocrine (NCNE) metastases lags behind that for colorectal and neuroendocrine types.
- This disparity is attributed to differences in tumor biology and historical limitations in systemic treatment options.
Purpose of the Study:
- To evaluate the role and potential benefits of liver resection for NCNE liver metastases.
- To highlight the evolving landscape of treatment for NCNE liver metastases with advancements in systemic therapies.
Main Methods:
- Review of current literature and clinical practice regarding liver resection for NCNE metastases.
- Analysis of the impact of recent advancements in systemic treatments on surgical decision-making.
Main Results:
- Selected chemotherapy-naive patients with NCNE liver metastases can achieve significant benefits from liver resection.
- Improvements in systemic treatments are enabling more effective multimodality approaches.
Conclusions:
- Liver resection is a viable option for select patients with NCNE liver metastases.
- Multimodality treatment concepts, integrating modern liver surgery, are increasingly important for managing these diverse tumors.
